« Back
Home /
Nivolumab

Nivolumab

Item no.	HY-P9903-1mg
Manufacturer	MedChem Express
CASRN	946414-94-4
Amount	1 mg
Quantity options	1 mg 25 mg 50 mg 5 mg
Category	Oncology Antibodies Primary Antibodies By Organ Lung Cancer
Type	Antibody Monoclonal
Specific against	other
Purity	99.63
Dry ice	Yes
Citations	[1]Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014 Sep;2(9):846-56.
Smiles	[Nivolumab]
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Alias	BMS-936558; ONO-4538; MDX-1106
Shipping condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	PD-1/PD-L1
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Product Description	Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
Manufacturer - Research Area	Cancer
Solubility	H2O
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P9903-1mg-safety-datasheet.pdf